Subtype
Colorectal Neoplasm
CI-CAN-00002404Explore in graph →
Non-malignant1,783 active trials21 approved drugs382 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002404Explore in graph →
Clinical trials
8,601 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05274204 | Individual Patient Expanded Access to CA102N | no longer available | — | — | Holy Stone Healthcare Co., LtdINDUSTRY | 0 | Sep 18, 2026 | clinicaltrials |
| NCT06195514 | Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC) | no longer available | — | — | TakedaINDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
| NCT04446793 |
| Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer |
| no longer available |
| — |
| — |
| Cardiff OncologyINDUSTRY |
| 0 |
| Feb 12, 2024 |
| clinicaltrials |
| NCT03554434 | An Expanded Access Program for AM0010 (Pegilodecakin) | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Mar 2, 2020 | clinicaltrials |
| NCT01538680 | Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy(CONSIGN) | no longer available | — | — | BayerINDUSTRY | 25 | May 29, 2019 | clinicaltrials |
| NCT02564224 | Study Comparing Pursestring Wound Closure vs Conventional Closure to Reverse Stoma of Colorectal Cancer Patients(PURSE) | no longer available | — | — | Zhejiang UniversityOTHER | 1 | Jun 6, 2018 | clinicaltrials |
Data updated 12 days agoSource updated Sep 18, 2026source: clinicaltrials